Anlon Healthcare IPO Subscription Status

The Anlon Healthcare IPO made a decent start on its first day of bidding (August 26, 2025, till 05:00 PM) with an overall subscription of 1.69 times.

• QIB (Qualified Institutional Buyers): 0.91x
• NII (Non-Institutional Investors): 0.71x
• RII (Retail Individual Investors): 8.99x

The company received bids for 2,24,54,224 shares against the issue size of 1,33,00,000 shares. The high demand from retail investors clearly reflects confidence in the company’s future growth prospects, though institutional participation is expected to strengthen on subsequent days.

About Anlon Healthcare Limited

Incorporated in 2013, Anlon Healthcare Limited is a rapidly expanding chemical and pharmaceutical manufacturer specializing in:

1. High-Purity Advanced Pharmaceutical Intermediates – Essential raw materials for producing APIs.
2. Active Pharmaceutical Ingredients (APIs) – Used in the formulation of medicines like tablets, capsules, ointments, syrups, nutraceuticals, personal care, and veterinary products.

The company’s product portfolio includes pharmaceutical intermediates, nutraceutical APIs, personal care ingredients, and veterinary-use APIs, giving it a well-diversified product base.

Key Highlight: Anlon Healthcare is among the few Indian companies producing Loxoprofen Sodium Dihydrate, an API widely prescribed for pain management (arthritis, frozen shoulder, dental pain, and post-surgery recovery).

As of January 31, 2025, the company employed 105 full-time employees (excluding trainees) and 8 contract workers. Additionally, it has:

• 65 commercial products
• 28 products in pilot stage
• 49 products under laboratory testing

This strong pipeline reflects the company’s R&D capabilities and future growth opportunities.

Strengths of Anlon Healthcare

• Diversified Portfolio: Presence across pharmaceuticals, nutraceuticals, animal health, and personal care sectors.
• Strong R&D Pipeline: Over 140+ products across commercial, pilot, and lab-testing stages.
• High Entry Barriers: Specialized products like Loxoprofen sodium dihydrate, with fewer competitors in India.
• Global Reach: Actively supplying APIs and intermediates to both domestic and international clients.
• Compliance & Quality: Manufacturing facilities designed to meet global standards, ensuring regulatory compliance.

Anlon Healthcare Financial Performance

Anlon Healthcare’s recent financials show mixed performance with a drop in revenue but a significant jump in profitability due to improved margins and cost efficiency.

• Revenue (FY 2023): ₹113.12 crore
• Revenue (FY 2024): ₹66.69 crore
• Profit (FY 2023): ₹5.82 crore
• Profit (FY 2024): ₹9.66 crore

Despite a 41% revenue decline, the company’s net profit grew by 65%, reflecting better operational efficiency and profitability management.

Anlon Healthcare IPO GMP (Grey Market Premium)

As of Tuesday, August 26, 2025, the Grey Market Premium (GMP) for Anlon Healthcare IPO stood at ₹6.

• IPO Issue Price: ₹91
• Grey Market Price: ₹97
• Premium: ₹6

This modest GMP suggests steady but cautious investor sentiment, indicating that while there is potential for listing gains, long-term growth will depend on the company’s ability to expand sales and sustain profitability.